TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023
March 29, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions...
TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
March 23, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical...
TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results
March 21, 2023 16:02 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 21, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications
March 16, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions...
TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 24, 2023 16:02 ET
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques
February 21, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical...
TELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization
February 14, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 20, 2023 16:05 ET
|
TELA Bio, Inc.
MALVERN, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds
January 09, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical...